Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
A diagnosis of a single plasmacytoma (SP), smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS) are all diagnostic terms of “PRE-Myeloma or Multiple Myeloma stage 0. While these diagnoses may lead to full-blown multiple myeloma, an incurable blood cancer, they are NOT cancer.
MGUS at a glance-
If you are newly diagnosed with SP, MGUS or SMM the standard instruction from a conventional oncologist to people who are diagnosed with these precursor stages of MM usually is to watch and wait.
These patients face several challenges. First and foremost, Pre-Multiple Myeloma can lead to full blown Multiple Myeloma. Mine did. I was diagnosed with a single plasmacytoma in early 1994. I progressed to full blown myeloma about a year later.
I wish I knew then what I know now.
The question on the minds of those diagnosed with pre-myeloma often is “what, if anything, can be done to remain pre-MM? Is there anything that can be done that is not chemotherapy aka toxic? I believe there is. I live an evidence-based, anti-MM lifestyle based on nutrition, supplementation, bone health and mind-body therapies that has kept me in complete remission since 1999. Curcumin, for example, has been show to reduce your risk of progressing to full-blown MM.
To learn more about the evidence-based, anti-MM lifestyle I’m talking about, please watch the short video below:
If you do not want to “watch and wait” to see if your pre-MM progresses to Multiple Myeloma scroll down the page, post a question or a comment and I will reply to you ASAP.
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplement that I take.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”